Biggest Battles in Biopharma

You know the picture: Two pharma CEOs, shaking hands and smiling as cameras flash and video rolls. It's been common enough, especially recently, as Pfizer and Wyeth, Merck and Schering-Plough announced their big mergers.

But that's not always the way M&A goes. While many pharma deals over the past 20 years have been relatively friendly, others haven't. Hostile bids, media grandstanding, warring press releases--unfriendly mergers have triggered them all.

The following list includes some of the biggest battles of the last two decades. We've covered a few of them ourselves, but others are before our time, such as Pfizer's Warner-Lambert takeover. Click below to get all the details on some of the industry's biggest takeover battles.
Click here to get started 

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.